After $60M Vertex deal, group of Catalyst shareholders claims biotech could’ve sold assets three years ago

Catalyst Biosciences was down to five employees in March, and the biotech needed to do something after two rounds of layoffs, a nixed collaboration and a culling of its hemophilia program. In came Vertex, with $60 million to buy up the South San Francisco biotech’s preclinical complement drugs, which target…

...

Click to view original post